Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls

Launched by UNIVERSITY OF CALGARY · Apr 11, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Healthy Population:
• • Adults aged 18 years and over
• • Able to understand the risks/benefits of the study
• • Able to give written informed consent
• • No active gastrointestinal symptoms or pathology
• • Resides in the Calgary, Alberta area
• Patient Population:
• • Adults aged 18 years and over
• • BMI \> 35
• • Able to understand the risks/benefits of the study
• • Able to give written informed consent
• • Patients meeting Rome IV Criteria for functional dyspepsia, or a nausea and vomiting disorder
• • Patients with gastroparesis defined on a standardized gastric scintigraphy study
• • Resides in the Calgary, Alberta area
• Exclusion Criteria:
• Healthy Population:
• • Under 18 years of age
• • BMI \> 35
• • Taking medications known to affect GI motility or the mid-gut axis (eg antidepressants, anti-anxiety medication, prokinetics, opiates)
• • Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism)
• • Known current GI infection (includes H. pylori when being actively treated)
• • Known current inflammatory bowel disease
• • Known current GI malignancy
• • Known GI functional or motility disorders
• • Previous gastroduodenal surgery
• • GI functional or motility disorders
• • Pregnant women
• • Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue)
• • Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily
• • Allergy to adhesives
• • History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar)
• • No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved
• • Regular cannabis use
• • Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger
• Patient Population:
• • Under 18 years of age
• • BMI \> 35
• • Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism)
• • Known current GI infection (includes H. pylori when being actively treated)
• • Known current inflammatory bowel disease
• • Known current GI malignancy
• • Previous gastroduodenal surgery
• • Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue)
• • Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily
• • Allergy to adhesives
• • Pregnant women
• • History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar)
• • No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved
• • Regular cannabis use except in the case of CHS
• • Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger
• • Inability to remain in a relaxed reclined position for the test duration